GSK's RSV vaccine candidate wins FDA priority review status
The US Food and Drug Administration has sent GSK’s potential respiratory syncytial virus vaccine down its speedy review path.
by ulrich quistgaard, translated by daniel pedersen
GSK can look forward to an accelerated approval process with the US Food and Drug Administration, FDA, after the authority has granted its priority review status to the British company’s RSV vaccine candidate.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.